Medication info
Trinam ER 5/1000 mg (Linagliptin, Metformin)

Trinam ER 5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
White, oval, extended-release film-coated tablet imprinted with IH 5/1000 on one side
Packaging
28 tablets (7 tablets/PTP × 4)/box, 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202400625 · Approved 2024.03.22 · Insurance code 640904630

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken with meals once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments should be made as appropriate. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the same as the current doses of linagliptin and extended-release metformin hydrochloride. Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dosage adjustment of this drug is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this drug may be used with dosage adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes when used alongside diet and exercise. Linagliptin and Metformin work together to help maintain stable blood sugar levels. Therefore, this medication greatly aids in managing diabetes and improving glucose control.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken with meals once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments should be made as appropriate. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the same as the current doses of linagliptin and extended-release metformin hydrochloride. Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dosage adjustment of this drug is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this drug may be used with dosage adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication may rarely cause severe lactic acidosis or hypoglycemia, so caution is needed. Patients who have an allergy to any component of this medication, or those with type 1 diabetes, severe renal or liver dysfunction should not use it. This medication should also not be administered in cases of severe infection, dehydration, severe trauma, or decreased heart function. Due to the risk of hypoglycemia, blood sugar should be monitored carefully when this medication is combined with insulin or sulfonylureas. Since renal function is critical, kidney function tests should be performed regularly before and during treatment, and this medication should not be used if renal function is severely impaired. It should be administered cautiously to patients with unstable heart function. If iodine contrast agents used in radiological examinations are received, this medication should be temporarily discontinued and can be resumed only after kidney function is confirmed to be normal post-examination. The use of this medication should be paused for a period before and after surgery and can only be resumed after renal function has recovered post-surgery. During the course of treatment with this medication, acute pancreatitis or bullous skin conditions (such as pemphigoid) may occur; if these symptoms arise, the patient should inform a doctor immediately and discontinue the drug. Long-term use can lead to vitamin B12 deficiency, so if symptoms of anemia or neurological disorders appear, vitamin B12 levels should be checked and supplementation should be administered if necessary. This medication should be swallowed whole and should not be crushed or chewed. The tablet shell may appear in the stool, but this is normal. This medication may interact with other drugs, so caution is needed when used alongside drugs that affect kidney function or hypoglycemic agents. It is advisable to avoid this medication during pregnancy or breastfeeding and to consult a doctor if pregnancy is planned. Safety and efficacy in pediatric patients have not been established. Elderly patients are at a higher risk of decreased renal function, thus requiring careful dosage adjustment and renal function testing. In cases of overdose, serious side effects like lactic acidosis may occur, necessitating immediate treatment at a hospital. This medication should be kept out of reach of children and stored away from moisture.

Side effects

  • severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
Show 109 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • itching
  • erythema
  • rash
  • similar to pemphigus
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reactions
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • colorectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • bruise
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • rhinorrhea
  • lung mass
  • joint pain
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • dermatitis
  • thyroid mass
  • confusional state
  • nocturia
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. The appropriate storage temperature is room temperature between 1 and 30 degrees Celsius, avoiding excessively hot or humid conditions.

Appearance and packaging

Appearance

White, oval, extended-release film-coated tablet imprinted with IH 5/1000 on one side

Package unit

28 tablets (7 tablets/PTP × 4)/box, 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.